ArmaGen Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ArmaGen Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010854
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ArmaGen Inc (ArmaGen), formerly ArmaGen Technologies Inc is a healthcare solution provide that discovers and develops novel therapies for the treatment of neurological disorders. The company’s pipeline portfolio includes AGT-181, AGT-182, AGT-183 and AGT-184 which are used for the treatment of neurological symptoms of lysosomal storage diseases. ArmaGen’s holds a pipeline of preclinical product candidates which are used to treat neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company’s technology platform solutions targets recombinant proteins, therapeutic monoclonal antibodies and siRNA to the brain. ArmaGen is headquartered in Calabasas, California, the US.

ArmaGen Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ArmaGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ArmaGen Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
ArmaGen Technologies Raises US$17 Million In Series A Financing 10
Partnerships 12
ArmaGen Enters into Research Agreement with Rett Syndrome Research Trust 12
Licensing Agreements 13
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 13
ArmaGen Inc – Key Competitors 14
ArmaGen Inc – Key Employees 15
ArmaGen Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Jan 19, 2017: ArmaGen Appoints Mathias Schmidt, Ph.D., as Chief Executive Officer 17
Product News 18
Jul 07, 2016: ArmaGen and Rett Syndrome Research Trust Collaborate to Develop Novel Therapeutic for the Treatment of Rett Syndrome 18
Clinical Trials 19
Feb 07, 2017: ArmaGen Announces Oral Presentation of Preliminary Results from its Phase 2 Clinical Trial of AGT-181 in Patients with MPS 1 to be Presented at WORLDSymposium 2017 19
Mar 31, 2016: ArmaGen Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial in Brazil to Study AGT-181 for the Treatment of Hurler Syndrome 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
ArmaGen Inc, Pharmaceuticals & Healthcare, Key Facts 2
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ArmaGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ArmaGen Inc, Deals By Therapy Area, 2011 to YTD 2017 8
ArmaGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ArmaGen Technologies Raises US$17 Million In Series A Financing 10
ArmaGen Enters into Research Agreement with Rett Syndrome Research Trust 12
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 13
ArmaGen Inc, Key Competitors 14
ArmaGen Inc, Key Employees 15

★海外企業調査レポート[ArmaGen Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Riot Blockchain Inc (RIOT)-医療機器分野:企業M&A・提携分析
    Summary Riot Blockchain Inc (Riot Blockchain), formerly known as Bioptix Inc, is an in-vitro diagnostic company focusing on development of blood-based tests in the diagnosis and treatment of acute appendicitis (AA) in children adolescent and young adult patients. Its product portfolio comprises APPY …
  • Siemens AG (SIE):製薬・医療:M&Aディール及び事業提携情報
    Summary Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution; oil and gas production and transportation; medical imagin …
  • Relief Therapeutics Holding AG (RLF):企業の財務・戦略的SWOT分析
    Summary Relief Therapeutics Holding AG (Relief Therapeutics) is a drug development company that offers clinical development of peptides and proteins of natural or engineered origin. Its pipeline drug candidates include aviptadil for the treatment of sarcoidosis and low dose interleukin-6 to treat pe …
  • Cytodyn Inc (CYDY):企業の財務・戦略的SWOT分析
    Summary Cytodyn Inc (Cytodyn), formerly RexRay Corp, is a biotechnology company. It develops and commercializes monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. It is investigating Leronlimab (PRO 140), a fully humanized IgG4 monoclonal antibody directed agai …
  • Schlumberger Ltd (SLB):石油・ガス:M&Aディール及び事業提携情報
    Summary Schlumberger Ltd (Schlumberger) is an oilfield services company that provides technology for reservoir characterization, drilling, production, and processing to the oil and gas industry. Schlumberger also supplies the industries with products and services, from exploration through production …
  • Hess Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Hess Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Hess Corp (Hess) is a global independent energy company which carries out the exploration and production of crude oil and natural gas. It primarily operates in US, Denmark, the Joint Development Area of Ma …
  • Saft Groupe SA:企業の戦略的SWOT分析
    Saft Groupe SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Genesco Inc.:企業の戦略・SWOT・財務情報
    Genesco Inc. - Strategy, SWOT and Corporate Finance Report Summary Genesco Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Curtiss-Wright Corp (CW):企業の財務・戦略的SWOT分析
    Curtiss-Wright Corp (CW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Flexera Software LLC:企業の戦略的SWOT分析
    Flexera Software LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Skyhawk Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Skyhawk Therapeutics Inc (Skyhawk) is a biotechnology company that discovers, develops and commercializes small molecule medicines that correct RNA expression. The company harnesses its STAR (Small molecule Therapies for Alternative splicing in RNA) platform, which combines information from …
  • Arthrex Inc:企業の戦略的SWOT分析
    Arthrex Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • ConforMIS Inc (CFMS):医療機器:M&Aディール及び事業提携情報
    Summary ConforMIS Inc (ConforMIS) is a medical technology company that manufactures, develops, and markets joint replacement implants. The company’s knee replacement implant products include iTotal CR a cruciate-retaining product, iTotal PS a posterior cruciate ligament substituting product, and iDu …
  • Windflow Technology Limited (WTL):企業の財務・戦略的SWOT分析
    Windflow Technology Limited (WTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Lantheus Medical Imaging Inc:企業の戦略的SWOT分析
    Lantheus Medical Imaging Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • ELMOS Semiconductor AG (ELG):企業の財務・戦略的SWOT分析
    ELMOS Semiconductor AG (ELG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Connect Group PLC (CNCT):企業の財務・戦略的SWOT分析
    Connect Group PLC (CNCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Engie SA (ENGI)-石油・ガス分野:企業M&A・提携分析
    Summary Engie S.A. (Engie), formerly GDF Suez S.A., is an electric utility, which generates and distributes electricity and natural gas. It generates electricity using various sources including hydro, wind, solar, biomass, geothermal, nuclear, coal and fuel oil. The company supplies, distributes, tr …
  • Paratek Pharmaceuticals Inc (PRTK):製薬・医療:M&Aディール及び事業提携情報
    Summary Paratek Pharmaceuticals Inc (Paratek) is a biopharmaceutical company that develops and commercializes therapies based on tetracycline chemistry. Omadacycline (antibiotic), the company’s lead product candidate is an aminomethylcycline which acts against gram-negative, gram-positive, and atypi …
  • Oil Search Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Oil Search Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Oil Search Ltd (Oil Search) is an independent upstream energy company. It explores for, develops and produces oil, natural gas and natural gas liquids (NGL). The company has majority of its oil and ga …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆